# Ammonium metabolism rewiring in the prostate cancer microenvironment: Mechanisms and clinical prospects

**Authors:** Zihao Ye, Hao Wu, Zhanhao Li, Ruizhe Ye, Yingliang Rao, Bin Liu, Baoshan Gao

PMC · DOI: 10.3389/fonc.2025.1673513 · Frontiers in Oncology · 2025-10-16

## TL;DR

This paper explores how ammonium metabolism influences prostate cancer development and the tumor environment, offering new therapeutic strategies.

## Contribution

The paper highlights the understudied role of ammonium metabolism in prostate cancer and proposes novel therapeutic strategies.

## Key findings

- Ammonium metabolism connects catabolic and anabolic pathways through key intermediates like α-ketoglutarate and citrate.
- Oncogenic drivers like Myc and p53 regulate enzymes in ammonium metabolism, promoting tumor progression.
- Ammonium metabolism contributes to immunosuppression and immune evasion in the tumor microenvironment.

## Abstract

Ammonium metabolism represents a critically understudied yet pivotal driver of prostate tumorigenesis and tumor microenvironment (TME) remodeling. The interplay between tumor metabolic reprogramming and the tumor microenvironment has emerged as a critical frontier in oncology research. While previous studies on prostate cancer metabolism have predominantly focused on lipid metabolism and the Warburg effect, the role of ammonium metabolism, particularly the urea cycle in tumor immune regulation remains insufficiently explored. This metabolic reprogramming constitutes a central node connecting catabolic nutrient breakdown to anabolic biosynthesis by integrating upstream amino acid deamination and transamination reactions with downstream pathways, generating key intermediates including α-ketoglutarate, coenzyme A, and citrate that concurrently fuel the tricarboxylic acid cycle and macromolecular synthesis. Crucially, oncogenic drivers such as Myc and p53 modulate this flux through epigenetic regulation of core enzymes such as glutaminase, glutamine synthetase and ornithine transcarbamylase, thereby channeling metabolism toward tumor progression. The immunomodulatory consequences manifest through dual mechanisms including TME immunosuppression driven by M2 macrophage polarization and immune evasion mediated via glutathione dependent redox homeostasis disruption. Beyond its established role in modulating redox homeostasis, ammonium metabolic reprogramming may additionally trigger novel cell death modalities such as ferroptosis by GSH/GPX4 axis. This emerging pathway offers promising therapeutic avenues for prostate cancer intervention. Synthesizing mechanistically validated insights from in vivo or in vitro models and clinical trials of ammonium-targeting inhibitors, this review proposes novel therapeutic strategies and candidate biomarkers. Moreover, the unique citrate and polyamine metabolism characteristics of prostate cancer may be impacted by these processes, offering promising avenues for future treatments.

## Linked entities

- **Genes:** MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609], TP53 (tumor protein p53) [NCBI Gene 7157], GSR2 (uncharacterized protein) [NCBI Gene 842935]
- **Chemicals:** ammonium (PubChem CID 223), coenzyme A (PubChem CID 87642), citrate (PubChem CID 31348), glutathione (PubChem CID 124886), GSH (PubChem CID 124886)
- **Diseases:** prostate cancer (MONDO:0005159)

## Full-text entities

- **Genes:** MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, OTC (ornithine transcarbamylase) [NCBI Gene 5009] {aka OCTD, OTC1, OTCD, OTCase}, GPX4 (glutathione peroxidase 4) [NCBI Gene 2879] {aka GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx}, GLUL (glutamate-ammonia ligase) [NCBI Gene 2752] {aka DEE116, GLNS, GS, PIG43, PIG59}, GLS (glutaminase) [NCBI Gene 2744] {aka AAD20, CASGID, DEE71, EIEE71, GAC, GAM}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}
- **Diseases:** tumorigenesis (MESH:D063646), prostate cancer (MESH:D011471), tumor (MESH:D009369)
- **Chemicals:** tricarboxylic acid (MESH:D014233), citrate (MESH:D019343), alpha-ketoglutarate (MESH:D007656), urea (MESH:D014508), polyamine (MESH:D011073), coenzyme A (MESH:D003065), GSH (MESH:D005978), lipid (MESH:D008055), Ammonium (MESH:D064751)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12571628/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12571628/full.md

## References

296 references — full list in the complete paper: https://tomesphere.com/paper/PMC12571628/full.md

---
Source: https://tomesphere.com/paper/PMC12571628